BRIEF-Calcimedica Reports Cash And Cash Equivalents Of About $34 Million As Graybug Vision Merger Close Expected To Support Operations Into H2 Of 2024

Reuters2023-03-21

March 20 (Reuters) - Graybug Vision Inc :

* CALCIMEDICA - CASH AND CASH EQUIVALENTS OF ABOUT $34 MILLION AS GRAYBUG VISION MERGER CLOSE EXPECTED TO SUPPORT OPERATIONS INTO SECOND HALF OF 2024

* CALCIMEDICA - PHASE 2B RESULTS IN ACUTE PANCREATITIS FOR LEAD PRODUCT CANDIDATE AUXORA™ EXPECTED IN Q4 2023

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2321539668?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-03-21 04:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2321539668","market":"us","top_or_hot":-1,"title":"BRIEF-Calcimedica Reports Cash And Cash Equivalents Of About $34 Million As Graybug Vision Merger Close Expected To Support Operations Into H2 Of 2024","media":"Reuters","content":"<html><body><p>March 20 (Reuters) - Graybug Vision Inc   :</p><p>   * CALCIMEDICA - CASH AND CASH EQUIVALENTS OF ABOUT $34 MILLION AS GRAYBUG VISION MERGER CLOSE EXPECTED TO SUPPORT OPERATIONS INTO SECOND HALF OF 2024</p><p>   * CALCIMEDICA - PHASE 2B RESULTS IN ACUTE PANCREATITIS FOR LEAD PRODUCT CANDIDATE AUXORA™ EXPECTED IN Q4 2023</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Calcimedica Reports Cash And Cash Equivalents Of About $34 Million As Graybug Vision Merger Close Expected To Support Operations Into H2 Of 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Calcimedica Reports Cash And Cash Equivalents Of About $34 Million As Graybug Vision Merger Close Expected To Support Operations Into H2 Of 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-03-21 04:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>March 20 (Reuters) - Graybug Vision Inc   :   * CALCIMEDICA - CASH AND CASH EQUIVALENTS OF ABOUT $34 MILLION AS GRAYBUG VISION MERGER CLOSE EXPECTED TO SUPPORT OPERATIONS INTO SECOND HALF OF 2024   * ...</p>\n\n<a href=\"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2321539668","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2321539668","pubTimestamp":1679344615,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"March 20 (Reuters) - Graybug Vision Inc   :   * CALCIMEDICA - CASH AND CASH EQUIVALENTS OF ABOUT $34","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","LHDX":"Lucira Health, Inc.","CALC":"CALCIMEDICA","CGEM":"Cullinan Therapeutics","BK4139":"生物科技","SANA":"Sana Biotechnology, Inc.","APR":"Apria, Inc.","BK4007":"制药","LABP":"Landos Biopharma, Inc.","BK4196":"保健护理服务"},"translate_title":"简介——Calcimedica报告称，随着Graybug Vision合并的完成，现金和现金等价物约为3400万美元，预计将支持2024年下半年的运营","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CALC":0.9,"GRAY":0.9,"APR":0.65,"CGEM":0.65,"LABP":0.65,"LHDX":0.65,"SANA":0.65},"content_text":"March 20 (Reuters) - Graybug Vision Inc   :   * CALCIMEDICA - CASH AND CASH EQUIVALENTS OF ABOUT $34 MILLION AS GRAYBUG VISION MERGER CLOSE EXPECTED TO SUPPORT OPERATIONS INTO SECOND HALF OF 2024   * CALCIMEDICA - PHASE 2B RESULTS IN ACUTE PANCREATITIS FOR LEAD PRODUCT CANDIDATE AUXORA™ EXPECTED IN Q4 2023Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2321539668"}